These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32852627)

  • 1. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
    Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
    Janssen JM; Jacobs BAW; Roosendaal J; Derissen EJB; Marchetti S; Beijnen JH; Huitema ADR; Dorlo TPC
    AAPS J; 2021 Jan; 23(1):23. PubMed ID: 33417061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
    Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.
    Chen M; Chen J; Peng X; Xu Z; Shao J; Zhu Y; Li G; Zhu H; Yang B; Luo P; He Q
    Environ Toxicol Pharmacol; 2017 Jan; 49():81-88. PubMed ID: 27951409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
    Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
    J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
    Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
    Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study.
    Scontre VA; Martins JC; de Melo Sette CV; Mutti H; Cubero D; Fonseca F; Del Giglio A
    J Diet Suppl; 2018 Sep; 15(5):606-612. PubMed ID: 29095653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen.
    Naito M; Yamamoto T; Hara S; Shimamoto C; Miwa Y
    Chemotherapy; 2017; 62(1):23-29. PubMed ID: 27229894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Elyasi S; Shojaee FSR; Allahyari A; Karimi G
    Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
    Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
    Trials; 2022 May; 23(1):420. PubMed ID: 35590388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
    King TL; Voon PJ; Yuen KH; Mohamed Noor DA
    Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
    Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
    Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
    Paule I; Tod M; Hénin E; You B; Freyer G; Girard P
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):447-55. PubMed ID: 21809035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Single-Blinded Phase II Trial Comparing Efficacy and Quality of Life of Topical Aloe Vera Gel Plus Urea Cream Versus Urea Cream Alone for Prevention of Hand Foot Syndrome in Cancer Patients Receiving Capecitabine.
    Wanichtanom L; Vrakornvoravuti G; Boonsiri M; Suthepwanon A
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):2203-2210. PubMed ID: 38918684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
    Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
    Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
    Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.